The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR

On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc. 

As opposed to patients with aortic stenosis, patients with AR had a higher migration index, more transcatheter reintervention, and greater surgical reintervention.

Additionally, only 25% of patients with severe AR are treated in the US, which shows us that this is an undertreated population. While using devices developed for aortic stenosis is accepted, they are off-label for AR, as they are not ideal for its anatomy, which opens up an opportunity to test specific devices.

Dr. Raj Makkar (USA)

Later, Dr. Ole De Backer (DEN) addressed the clinical implications of imaging findings, such as reduced leaflet motion or their hypoattenuation (HALT).

Through tomographic studies with adequate follow-up, these issues might not impact transvalvular gradient, thromboembolic events, or mortality. The only affected parameter was eventual long term durability (hypothesis).

He discouraged the systematic search for this problem; it should only be suspected in patients with a mean gradient >10 mmHg, early degeneration, or a neurological event unrelated to another cause.

Dr. Ole de Backer (DNK)
Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...